Reactivaion of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma
Background. The development of unique immune-related adverse events (irAEs) is a known hallmark of immunotherapy. Generally, such complications occur during the first 3–6 months of immunotherapy, however, the experience with immune checkpoint inhibitors (ICIs) shows that irAEs can also occur after c...
Saved in:
| Main Authors: | E. A. Degtiareva, S. A. Protsenko, E. N. Imyanitov, G. M. Teletaeva, D. Kh. Latipova, A. I. Semenova, A. V. Novik |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2022-11-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/2322 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Spontaneous haematoma: A unique immune-related adverse event alongside other cutaneous reactions in a patient treated with pembrolizumab for metastatic melanoma
by: Dalila Malek, et al.
Published: (2024-12-01) -
Immune checkpoint inhibitors for the treatment of solid tumors in HIV-infected patients: is it worth the risk?
by: E. A. Degtiareva, et al.
Published: (2023-02-01) -
Incidence Rates of Cutaneous Immune-Related Adverse Events in Patients with Lung Cancer: A Systematic Review and Meta-Analysis
by: Zhihui Yang, et al.
Published: (2025-03-01) -
Immunotherapy in Advanced Cutaneous Melanoma: From the Optimal Treatment Duration to the Impact on Survival in Case of Early Discontinuation Due to Immune-Related Adverse Events
by: Giacomo Triggiano, et al.
Published: (2025-04-01) -
Exploring the Dynamics of Immune Checkpoint Inhibitor‐Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis
by: Panagiotis T. Diamantopoulos, et al.
Published: (2025-04-01)